8019 Background: Various new agents have been introduced recently to treat relapsed/refractory multiple myeloma (RRMM), yet the chronification of the disease requires additional options for patients (pts) in advanced stages. Here, effectiveness and tolerability are important. Many advanced pts have received little chemotherapy but may suffer from peripheral neuropathy (PN). Carfilzomib (K) is a potent novel proteasome inhibitor not inducing significant PN. K was combined with bendamustine (B) to achieve synergistic effects. KB with low-dose dexamethasone (d) was tested in RRMM pts in a phase 1/2 trial (NCT02056756). Methods: 63 RRMM pts with ≥2 lines of prior therapy received KBd. Therapy consisted of 8 28-day courses of B at 70 mg/m2 day 1,8; K at 27 mg/m2 (initially 20 mg/m2) day 1,2,8,9,15,16; d at 20 mg on every treatment day plus day 22,23. Responding pts received Kd maintenance every 14 days until PD. In the phase 1, a dose escalation in 6 pts to K at 36 mg/m2 was attempted but led to 2 dose limiting toxicities. Thus, the phase 2 was conducted with K at 27 mg/m2. Results: Pts had a median age of 66 years (range 37-79) and presented with RRMM in a median of 5.2 years after diagnosis. They were extensively pretreated, with a median of 4 prior lines (range 2-9) and 75% had previously received autologous stem cell transplantation, 87% bortezomib and 86% immunomodulatory drugs. At least VGPR rate was 32%, including 18% CR/sCR/nCR; 19% of pts achieved PR, 41% SD, 8% PD. Median PFS was 11.6 months, median OS 24.0 months. 1-year PFS was 72% in standard-risk and 35% in high-risk cytogenetics pts. Infections, particularly pneumonia, cardiac and thromboembolic adverse events (AEs) were the most frequent non-hematological AEs of grade ≥3; 51% of pts experienced ≥1 severe AE. Also the hematological toxicity was manageable. Conclusions: KBd was effective and well-tolerated in advanced RRMM pts requiring treatment rather late in the course of their disease. This cost-effective combination therapy with K at the 20/27 mg/m2 and B at 70 mg/m2 can be applied in an outpatient setting, with no significant nausea, hair loss or PN. Yet, cardiopulmonary and vascular signs need attention and infection prophylaxis is mandatory in these immunosuppressed pts. Clinical trial information: NCT02056756.